Prostanoids as pharmacological targets in COPD and asthma

European Journal of Pharmacology

Volumn 533, Issue 1-3, 2006, Pages 89-100

  Rolin, Stéphanie ^a   Masereel, Bernard ^a   Dogné, Jean Michel ^a,b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Isoprostanes; Prostanoid

Indexed keywords

ANTIASTHMATIC AGENT; INDOMETACIN; ISOPROSTANE; ISOPROSTANE DERIVATIVE; K117; K604; L 888607; OZAGREL; PHOSPHOLIPID; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; PROSTANOID; RAMATROBAN; REACTIVE OXYGEN METABOLITE; SERATRODAST; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

AIRWAY; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; HUMAN; LUNG DISEASE; PATHOPHYSIOLOGY; PEROXIDATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ASTHMA; BENZOQUINONES; CARBAZOLES; ENZYME INHIBITORS; F2-ISOPROSTANES; HEPTANOIC ACIDS; HUMANS; METHACRYLATES; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDIN D2; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SULFONAMIDES; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 33644746168     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.12.058     Document Type: Review

References (156)

1. M. Abramovitz, Y. Boie, T. Nguyen, T.H. Rushmore, M.A. Bayne, K.M. Metters, D.M. Slipetz, and R. Grygorczyk Cloning and expression of a cDNA for the human prostanoid FP receptor J. Biol. Chem. 269 1994 2632 2636
2. H. Aizawa, M. Shigyo, H. Nogami, T. Hirose, and N. Hara BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics Chest 109 1996 338 342
3. Y. Arakida, K. Ohga, S. Kobayashi, M. Yokota, K. Miyata, T. Yamada, and K. Honda Binding of YM158, a new dual antagonist for leukotriene D4 and thromboxane A2 receptors, to guinea pig lung membranes Eur. J. Pharmacol. 362 1998 229 233
4. Y. Arakida, K. Suwa, K. Ohga, M. Yokota, K. Miyata, T. Yamada, and K. Honda In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors J. Pharmacol. Exp. Ther. 287 1998 633 639
5. Y. Arakida, K. Ohga, K. Suwa, Y. Okada, H. Morio, M. Yokota, K. Miyata, T. Yamada, and K. Honda Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyper-responsiveness in guinea pigs Jpn. J. Pharmacol. 82 2000 287 294
6. Y. Arakida, K. Ohga, K. Suwa, Y. Okada, H. Morio, M. Yokota, K. Miyata, T. Yamada, and K. Honda In vivo pharmacologic profile of YM158, a new dual antagonist for leukotriene D4 and thromboxane A2 receptors Jpn. J. Pharmacol. 83 2000 63 72
7. Y. Ashida, T. Matsumoto, H. Kuriki, M. Shiraishi, K. Kato, and S. Terao A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids Prostaglandins 38 1989 91 112
8. J.A. Awad, J.D. Morrow, K. Takahashi, and L.J. Roberts II Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma J. Biol. Chem. 268 1993 4161 4169
9. C. Bachert, P. van Cauwenberge, N. Khaltaev, and J. Bousquet Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland Allergy 57 2002 841 855
10. P.J. Barnes Mechanisms in COPD: differences from asthma Chest 117 2000 10S 14S
11. P.J. Barnes Mediators of chronic obstructive pulmonary disease Pharmacol. Rev. 56 2004 515 548
12. P.J. Barnes, K.F. Chung, and C.P. Page Inflammatory mediators of asthma: an update Pharmacol. Rev. 50 1998 515 596
13. Y. Boie, T.H. Rushmore, A. Darmon-Goodwin, R. Grygorczyk, D.M. Slipetz, K.M. Metters, and M. Abramovitz Cloning and expression of a cDNA for the human prostanoid IP receptor J. Biol. Chem. 269 1994 12173 12178
14. Y. Boie, N. Sawyer, D.M. Slipetz, K.M. Metters, and M. Abramovitz Molecular cloning and characterization of the human prostanoid DP receptor J. Biol. Chem. 270 1995 18910 18916
15. C.L. Bos, D.J. Richel, T. Ritsema, M.P. Peppelenbosch, and H.H. Versteeg Prostanoids and prostanoid receptors in signal transduction Int. J. Biochem. Cell Biol. 36 2004 1187 1205
16. J. Bousquet, P.K. Jeffery, W.W. Busse, M. Johnson, and A.M. Vignola Asthma. From bronchoconstriction to airways inflammation and remodeling Am. J. Respir. Crit. Care Med. 161 2000 1720 1745
17. J. Bousquet, I.J. Ansotegui, R. van Ree, P.G. Burney, T. Zuberbier, and P. van Cauwenberge European Union meets the challenge of the growing importance of allergy and asthma in Europe Allergy 59 2004 1 4
18. R.M. Breyer, C.K. Bagdassarian, S.A. Myers, and M.D. Breyer Prostanoid receptors: subtypes and signaling Annu. Rev. Pharmacol. Toxicol. 41 2001 661 690
19. W.J. Calhoun, H.E. Reed, D.R. Moest, and C.A. Stevens Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects Am. Rev. Respir. Dis. 145 1992 317 325
20. V. Capra, A. Habib, M.R. Accomazzo, S. Ravasi, S. Citro, S. Levy-Toledano, S. Nicosia, and G.E. Rovati Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation Eur. J. Pharmacol. 474 2003 149 159
21. C.R. Cardoso, F.C. de Brito, K.C. da Silva, A.L. de Miranda, C.A. Fraga, and E.J. Barreiro Design, synthesis and pharmacological evaluation of novel pyrazolo[3,4-b]thieno[2,3-d]pyridine acid derivatives: a new class of anti-inflammatory and anti-platelet agents Bioorg. Med. Chem. Lett. 12 2002 9 12
22. S. Castellani, B. Paladini, R. Paniccia, C. Di Serio, B. Vallotti, A. Ungar, S. Fumagalli, C. Cantini, L. Poggesi, and G.G. Neri Serneri Increased renal formation of thromboxane A2 and prostaglandin F2 alpha in heart failure Am. Heart J. 133 1997 94 100
23. M.S. Chesnutt Management of asthma exacerbations Clin. Cornerstone 4 2002 1 17
24. R.A. Coleman, and R.L. Sheldrick Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors Br. J. Pharmacol. 96 1989 688 692
25. R.A. Coleman, W.L. Smith, and S. Narumiya International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes Pharmacol. Rev. 46 1994 205 229
26. G. Davi, S. Basili, M. Vieri, F. Cipollone, S. Santarone, C. Alessandri, P. Gazzaniga, C. Cordova, and F. Violi Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group Am. J. Respir. Crit. Care Med. 156 1997 1794 1799
27. R.J. Davis, C.E. Murdoch, M. Ali, S. Purbrick, R. Ravid, G.S. Baxter, N. Tilford, R.L. Sheldrick, K.L. Clark, and R.A. Coleman EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries Br. J. Pharmacol. 141 2004 580 585
28. P. Demoly, D. Jaffuel, N. Lequeux, B. Weksler, C. Creminon, F.B. Michel, P. Godard, and J. Bousquet Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics Am. J. Respir. Crit. Care Med. 155 1997 670 675
29. P. Devillier, and G. Bessard Thromboxane A2 and related prostaglandins in airways Fundam. Clin. Pharmacol. 11 1997 2 18
30. J.M. Dogne, X. de Leval, P. Benoit, J. Delarge, and B. Masereel Thromboxane A2 inhibition: therapeutic potential in bronchial asthma Am. J. Respir. Medicine 1 2002 11 17
31. J.M. Dogne, X. de Leval, P. Benoit, S. Rolin, B. Pirotte, and B. Masereel Therapeutic potential of thromboxane inhibitors in asthma Expert Opin. Investig. Drugs 11 2002 275 281
32. J.M. Dogne, X. de Leval, J. Hanson, M. Frederich, B. Lambermont, A. Ghuysen, A. Casini, B. Masereel, K.H. Ruan, B. Pirotte, and P. Kolh New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators Curr. Med. Chem. 11 2004 1223 1241
33. G.W. Dorn II, and M.W. Becker Thromboxane A2 stimulated signal transduction in vascular smooth muscle J. Pharmacol. Exp. Ther. 265 1993 447 456
34. R.N. Dubois, S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, L.B. Van De Putte, and P.E. Lipsky Cyclooxygenase in biology and disease FASEB J. 12 1998 1063 1073
35. R. Dworski, J.J. Murray, L.J. Roberts II, J.A. Oates, J.D. Morrow, L. Fisher, and J.R. Sheller Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress Am. J. Respir. Crit. Care Med. 160 1999 1947 1951
36. R. Dworski, L.J. Roberts II, J.J. Murray, J.D. Morrow, T.V. Hartert, and J.R. Sheller Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha) Clin. Exp. Allergy 31 2001 387 390
37. D.L. Emery, T.D. Djokic, P.D. Graf, and J.A. Nadel Prostaglandin D2 causes accumulation of eosinophils in the lumen of the dog trachea J. Appl. Physiol. 67 1989 959 962
38. J.E. Fish, L.S. Jameson, A. Albright, and P.S. Norman Modulation of the bronchomotor effects of chemical mediators by prostaglandin F2 alpha in asthmatic subjects Am. Rev. Respir. Dis. 130 1984 571 574
39. G.A. FitzGerald, and C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N. Engl. J. Med. 345 2001 433 442
40. H.P. Francis, T.G. Morris, A.M. Thompson, U.P. Patel, and P.J. Gardiner The thromboxane receptor antagonist BAY u3405 reverses prostaglandin D2 (PGD2)-induced bronchoconstriction in the anaesthetised guinea pig Ann. N.Y. Acad. Sci. 629 1991 399 401
41. M. Fujimura, F. Sasaki, Y. Nakatsumi, Y. Takahashi, S. Hifumi, K. Taga, J. Mifune, T. Tanaka, and T. Matsuda Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects Thorax 41 1986 955 959
42. M. Fujimura, Y. Miyake, K. Uotani, K. Kanamori, and T. Matsuda Secondary release of thromboxane A2 in aerosol leukotriene C4-induced bronchoconstriction in guinea pigs Prostaglandins 35 1988 427 435
43. M. Fujimura, S. Nishioka, I. Kumabashiri, T. Matsuda, and J. Mifune Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects Chest 98 1990 276 279
44. M. Fujimura, S. Sakamoto, and T. Matsuda Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma Chest 98 1990 656 660
45. M. Fukunaga, N. Makita, L.J. Roberts II, J.D. Morrow, K. Takahashi, and K.F. Badr Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells Am. J. Physiol. 264 1993 C1619 C1624
46. P.J. Gardiner Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979 Br. J. Pharmacol. 87 1986 45 56
47. F.G. Gervais, J.P. Morello, C. Beaulieu, N. Sawyer, D. Denis, G. Greig, A.D. Malebranche, and G.P. O'Neill Identification of a potent and selective synthetic agonist at the CRTH2 receptor Mol. Pharmacol. 67 2005 1834 1839
48. I.P. Hall Second messengers, ion channels and pharmacology of airway smooth muscle Eur. Respir. J. 15 2000 1120 1127
49. M. Hamberg, J. Svensson, and B. Samuelsson Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides Proc. Natl. Acad. Sci. U. S. A. 72 1975 2994 2998
50. C.C. Hardy, C. Robinson, A.E. Tattersfield, and S.T. Holgate The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men N. Engl. J. Med. 311 1984 209 213
51. A.N. Hata, and R.M. Breyer Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation Pharmacol. Ther. 103 2004 147 166
52. A.N. Hata, T.P. Lybrand, L.J. Marnett, and R.M. Breyer Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2 Mol. Pharmacol. 67 2005 640 647
53. R.L. Hebert, T. O'Connor, C. Neville, K.D. Burns, O. Laneuville, and L.N. Peterson Prostanoid signaling, localization, and expression of IP receptors in rat thick ascending limb cells Am. J. Physiol. 275 1998 F904 F914
54. G.A. Higgs, S. Moncada, J.A. Salmon, and K. Seager The source of thromboxane and prostaglandins in experimental inflammation Br. J. Pharmacol. 79 1983 863 868
55. H. Hirai, K. Tanaka, O. Yoshie, K. Ogawa, K. Kenmotsu, Y. Takamori, M. Ichimasa, K. Sugamura, M. Nakamura, S. Takano, and K. Nagata Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 J. Exp. Med. 193 2001 255 261
56. H. Hirai, K. Tanaka, S. Takano, M. Ichimasa, M. Nakamura, and K. Nagata Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2 J. Immunol. 168 2002 981 985
57. M. Hirata, Y. Hayashi, F. Ushikubi, Y. Yokota, R. Kageyama, S. Nakanishi, and S. Narumiya Cloning and expression of cDNA for a human thromboxane A2 receptor Nature 349 1991 617 620
58. T. Hirata, F. Ushikubi, A. Kakizuka, M. Okuma, and S. Narumiya Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation J. Clin. Invest. 97 1996 949 956
59. J.S. Huang, S.K. Ramamurthy, X. Lin, and G.C. Le Breton Cell signalling through thromboxane A2 receptors Cell. Signal. 16 2004 521 533
60. T. Imai, M. Adachi, K. Idaira, T. Suganuma, T. Takahashi, H. Yamaguchi, C. Saito, M. Maeda, and A. Tsuji The effect of a specific thromboxane A2 antagonist, AA-2414 on airway hyperresponsiveness induced by ozone exposure in dogs Arerugi 40 1991 28 36
61. Y. Ishitsuka, H. Moriuchi, K. Hatamoto, C. Yang, J. Takase, S. Golbidi, M. Irikura, and T. Irie Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs J. Pharm. Pharmacol. 56 2004 513 520
62. T. Ishizuka, T. Matsui, Y. Okamoto, A. Ohta, and M. Shichijo Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor Cardiovasc. Drug Rev. 22 2004 71 90
63. H. Itoh, K. Yamatani, N. Oshida, M. Shioi, M. Takaba, H. Kamiyama, and M. Itoh Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery No To Shinkei 50 1998 147 155
64. I. Iwamoto, T. Umibe, H. Nakajima, and S. Yoshida Effect of a selective thromboxane A2 receptor antagonist BAY u3405 on antigen-, leukotriene C4- and leukotriene D4-induced bronchoconstriction in guinea pigs Int. Arch. Allergy Immunol. 108 1995 68 73
65. Z. Jaffar, K.S. Wan, and K. Roberts A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen J. Immunol. 169 2002 5997 6004
66. L.J. Janssen Isoprostanes: an overview and putative roles in pulmonary pathophysiology Am. J. Physiol., Lung Cell Mol. Physiol. 280 2001 L1067 L1082
67. L.J. Janssen, M. Premji, S. Netherton, A. Catalli, G. Cox, S. Keshavjee, and D.J. Crankshaw Excitatory and inhibitory actions of isoprostanes in human and canine airway smooth muscle J. Pharmacol. Exp. Ther. 295 2000 506 511
68. L.J. Janssen, M. Premji, S. Netherton, J. Coruzzi, H. Lu-Chao, and P.G. Cox Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles Br. J. Pharmacol. 132 2001 127 134
69. L.J. Janssen, A. Catalli, and P. Helli The pulmonary biology of isoprostanes Antioxid. Redox Signal. 7 2005 244 255
70. P.K. Jeffery Structural and inflammatory changes in COPD: a comparison with asthma Thorax 53 1998 129 136
71. T.H. Ji, M. Grossmann, and I. Ji G protein-coupled receptors. I. Diversity of receptor-ligand interactions J. Biol. Chem. 273 1998 17299 17302
72. G.L. Jones, H.G. Saroea, R.M. Watson, and P.M. O'Byrne Effect of an inhaled thromboxane mimetic (U46619) on airway function in human subjects Am. Rev. Respir. Dis. 145 1992 1270 1274
73. K. Kabashima, and S. Narumiya The DP receptor, allergic inflammation and asthma Prostaglandins Leukot. Essent. Fat. Acids 69 2003 187 194
74. I. Kawikova, P.J. Barnes, T. Takahashi, S. Tadjkarimi, M.H. Yacoub, and M.G. Belvisi 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro Am. J. Respir. Crit. Care Med. 153 1996 590 596
75. B.T. Kinsella, D.J. O'Mahony, and G.A. Fitzgerald The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha J. Pharmacol. Exp. Ther. 281 1997 957 964
76. T. Kobayashi, and S. Narumiya Function of prostanoid receptors: studies on knockout mice Prostaglandins Other Lipid Mediat. 68-69 2002 557 573
77. K.D. Kochanek, S.L. Murphy, R.N. Anderson, and C. Scott Deaths: final data for 2002 Natl. Vital. Stat. Rep. 53 2004 1 115
78. Y. Komatsu, and N. Minami Synthesis of a novel dual inhibitor of thromboxane A2 synthetase and 5-lipoxygenase (E3040) via the direct coupling reaction of hydroquinone with 3-pyridinecarboxaldehyde Chem. Pharm. Bull. (Tokyo) 43 1995 1614 1616
79. M. Kumlin, B. Dahlen, T. Bjorck, O. Zetterstrom, E. Granstrom, and S.E. Dahlen Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics Am. Rev. Respir. Dis. 146 1992 96 103
80. M. Kurosawa Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma Clin. Ther. 17 1995 2 11 discussion 11
81. R.A. Lewis, N.A. Soter, P.T. Diamond, K.F. Austen, J.A. Oates, and L.J. Roberts II Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE J. Immunol. 129 1982 1627 1631
82. H. Magnussen, S. Boerger, K. Templin, and A.R. Baunack Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction J. Allergy Clin. Immunol. 89 1992 1119 1126
83. J.M. Mathiesen, T. Ulven, L. Martini, L.O. Gerlach, A. Heinemann, and E. Kostenis Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2 Mol. Pharmacol. 68 2005 393 402
84. T. Matsumoto, and Y. Ashida Inhibition of antigen-induced airway hyperresponsiveness by a thromboxane A2 receptor antagonist (AA-2414) in Ascaris suum-allergic dogs Prostaglandins 46 1993 301 318
85. T. Matsumoto, Y. Ashida, and R. Tsukuda Pharmacological modulation of immediate and late airway response and leukocyte infiltration in the guinea pig J. Pharmacol. Exp. Ther. 269 1994 1236 1244
86. T. Matsuoka, M. Hirata, H. Tanaka, Y. Takahashi, T. Murata, K. Kabashima, Y. Sugimoto, T. Kobayashi, F. Ushikubi, Y. Aze, N. Eguchi, Y. Urade, N. Yoshida, K. Kimura, A. Mizoguchi, Y. Honda, H. Nagai, and S. Narumiya Prostaglandin D2 as a mediator of allergic asthma Science 287 2000 2013 2017
87. M.G. McKenniff, P. Norman, N.J. Cuthbert, and P.J. Gardiner BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro Br. J. Pharmacol. 104 1991 585 590
88. H. Mimura, T. Ikemura, O. Kotera, M. Sawada, S. Tashiro, E. Fuse, K. Ueno, H. Manabe, E. Ohshima, A. Karasawa, and H. Miyaji Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2 J. Pharmacol. Exp. Ther. 314 2005 244 251
89. P. Montuschi, G. Ciabattoni, P. Paredi, P. Pantelidis, R.M. du Bois, S.A. Kharitonov, and P.J. Barnes 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases Am. J. Respir. Crit. Care Med. 158 1998 1524 1527
90. P. Montuschi, M. Corradi, G. Ciabattoni, J. Nightingale, S.A. Kharitonov, and P.J. Barnes Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients Am. J. Respir. Crit. Care Med. 160 1999 216 220
91. P. Montuschi, J.V. Collins, G. Ciabattoni, N. Lazzeri, M. Corradi, S.A. Kharitonov, and P.J. Barnes Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers Am. J. Respir. Crit. Care Med. 162 2000 1175 1177
92. H.G. Morris, N.A. Sherman, F.T. Shepperdson, and J.C. Selner Radioimmunoassay of thromboxane B2 in plasma of normal and asthmatic subjects Adv. Prostaglandin Thromboxane Res. 8 1980 1759 1764
93. J.D. Morrow, and L.J. Roberts II The isoprostanes. Current knowledge and directions for future research Biochem. Pharmacol. 51 1996 1 9
94. J.D. Morrow, and L.J. Roberts The isoprostanes: unique bioactive products of lipid peroxidation Prog. Lipid Res. 36 1997 1 21
95. J.D. Morrow, and L.J. Roberts II Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress Methods Enzymol. 300 1999 3 12
96. J.D. Morrow, and L.J. Roberts The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease Am. J. Respir. Crit. Care Med. 166 2002 S25 S30
97. J.D. Morrow, K.E. Hill, R.F. Burk, T.M. Nammour, K.F. Badr, and L.J. Roberts II A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc. Natl. Acad. Sci. U. S. A. 87 1990 9383 9387
98. J.D. Morrow, J.A. Awad, A. Wu, W.E. Zackert, V.C. Daniel, and L.J. Roberts II Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo J. Biol. Chem. 271 1996 23185 23190
99. T. Murata, F. Ushikubi, T. Matsuoka, M. Hirata, A. Yamasaki, Y. Sugimoto, A. Ichikawa, Y. Aze, T. Tanaka, N. Yoshida, A. Ueno, S. Oh-ishi, and S. Narumiya Altered pain perception and inflammatory response in mice lacking prostacyclin receptor Nature 388 1997 678 682
100. J.J. Murray, A.B. Tonnel, A.R. Brash, L.J. Roberts II, P. Gosset, R. Workman, A. Capron, and J.A. Oates Release of prostaglandin D2 into human airways during acute antigen challenge N. Engl. J. Med. 315 1986 800 804
101. K. Nagata, and H. Hirai The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes Prostaglandins Leukot. Essent. Fat. Acids 69 2003 169 177
102. K. Nagata, H. Hirai, K. Tanaka, K. Ogawa, T. Aso, K. Sugamura, M. Nakamura, and S. Takano CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s) FEBS Lett. 459 1999 195 199
103. M. Nakazawa, K. Iizuka, A. Ujiie, S. Hiraku, and S. Ohki Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase Yakugaku Zasshi 114 1994 911 933
104. T. Namba, H. Oida, Y. Sugimoto, A. Kakizuka, M. Negishi, A. Ichikawa, and S. Narumiya cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla J. Biol. Chem. 269 1994 9986 9992
105. F. Nambu, T. Shiraji, M. Motoishi, M. Sawada, N. Omawari, H. Terashima, T. Okegawa, A. Kawasaki, and S. Ikeda Effect of an oral thromboxane synthetase inhibitor (OKY-046) on antigen-induced bronchoconstriction in guinea pigs Adv. Prostaglandin Thromboxane Leukotriene Res. 19 1989 528 530
106. F. Nambu, N. Yube, N. Omawari, M. Sawada, T. Okegawa, A. Kawasaki, and S. Ikeda Inhibition of endothelin-induced bronchoconstriction by OKY-046, a selective thromboxane A2 synthetase inhibitor, in guinea pigs Adv. Prostaglandin Thromboxane Leukotriene Res. 21A 1991 453 456
107. S. Narumiya, Y. Sugimoto, and F. Ushikubi Prostanoid receptors: structures, properties, and functions Physiol. Rev. 79 1999 1193 1226
108. R. Newton, L.M. Kuitert, M. Bergmann, I.M. Adcock, and P.J. Barnes Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta Biochem. Biophys. Res. Commun. 237 1997 28 32
109. X. Norel, C. Labat, P. Gardiner, and C. Brink Prostanoid contractions in human isolated pulmonary muscle preparations: inhibition by BAY u3405 Adv. Prostaglandin Thromboxane Leukotriene Res. 21A 1991 473 476
110. X. Norel, C. Labat, P.J. Gardiner, and C. Brink Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations Br. J. Pharmacol. 104 1991 591 595
111. P. Norman, N.J. Cuthbert, P.J. Gardiner, and M.G. McKenniff BAY u3405 is a potent and competitive antagonist of U46619, PGD2 and 9 alpha, 11 beta PGF2 alpha-induced contractions of airway smooth muscle Ann. N.Y. Acad. Sci. 629 1991 396 398
112. R. Nusing, R. Lesch, and V. Ullrich Immunohistochemical localization of thromboxane synthase in human tissues Eicosanoids 3 1990 53 58
113. J.A. Oates, G.A. FitzGerald, R.A. Branch, E.K. Jackson, H.R. Knapp, and L.J. Roberts II Clinical implications of prostaglandin and thromboxane A2 formation (1) N. Engl. J. Med. 319 1988 689 698
114. K. Oketani, T. Inoue, and M. Murakami Effect of E3040, an inhibitor of 5-lipoxygenase and thromboxane synthase, on rat bowel damage induced by lipopolysaccharide Eur. J. Pharmacol. 427 2001 159 166
115. K. Oketani, N. Nagakura, K. Harada, and T. Inoue In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production Eur. J. Pharmacol. 422 2001 209 216
116. L. Oliveira, N.A. Stallwood, and D.J. Crankshaw Effects of some isoprostanes on the human umbilical artery in vitro Br. J. Pharmacol. 129 2000 509 514
117. Y. Oosterhoff, H.F. Kauffman, B. Rutgers, F.J. Zijlstra, G.H. Koeter, and D.S. Postma Inflammatory cell number and mediators in bronchoalveolar lavage fluid and peripheral blood in subjects with asthma with increased nocturnal airways narrowing J. Allergy Clin. Immunol. 96 1995 219 229
118. J.L. Parent, P. Labrecque, M.J. Orsini, and J.L. Benovic Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced COOH terminus in agonist-promoted receptor internalization J. Biol. Chem. 274 1999 8941 8948
119. K.L. Pierce, T.J. Bailey, P.B. Hoyer, D.W. Gil, D.F. Woodward, and J.W. Regan Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor J. Biol. Chem. 272 1997 883 887
120. D. Pratico, S. Basili, M. Vieri, C. Cordova, F. Violi, and G.A. Fitzgerald Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress Am. J. Respir. Crit. Care Med. 158 1998 1709 1714
121. K.F. Rabe, and D.T. Schmidt Pharmacological treatment of asthma today Eur. Respir. J. Suppl. 34 2001 34s 40s
122. K. Rajakulasingam, S.L. Johnston, J. Ducey, W. Ritter, P.H. Howarth, and S.T. Holgate Effect of thromboxane A2-receptor antagonist on bradykinin-induced bronchoconstriction in asthma J. Appl. Physiol. 80 1996 1973 1977
123. M.K. Raychowdhury, M. Yukawa, L.J. Collins, S.H. McGrail, K.C. Kent, and J.A. Ware Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor J. Biol. Chem. 269 1994 19256 19261
124. L.J. Roberts II, B.J. Sweetman, R.A. Lewis, K.F. Austen, and J.A. Oates Increased production of prostaglandin D2 in patients with systemic mastocytosis N. Engl. J. Med. 303 1980 1400 1404
125. J. Rokach, S.P. Khanapure, S.W. Hwang, M. Adiyaman, J.A. Lawson, and G.A. FitzGerald Nomenclature of isoprostanes: a proposal Prostaglandins 54 1997 853 873
126. H. Sakai, T. Suzuki, M. Murota, K. Oketani, T. Uchiumi, M. Murakami, and N. Takeguchi E3040 sulphate, a novel thromboxane synthase inhibitor, blocks the Cl-secretion induced by platelet-activating factor in isolated rat colon Br. J. Pharmacol. 136 2002 383 390
127. T. Sakurai, S. Yamaguchi, T. Iwama, and H. Nagai Pharmacological studies of platelet-activating factor (PAF)-induced augmentation of response to histamine in guinea-pigs Prostaglandins Leukot. Essent. Fat. Acids 51 1994 95 99
128. S.P. Sanders, J.L. Zweier, S.J. Harrison, M.A. Trush, S.J. Rembish, and M.C. Liu Spontaneous oxygen radical production at sites of antigen challenge in allergic subjects Am. J. Respir. Crit. Care Med. 151 1995 1725 1733
129. A. Shenker, P. Goldsmith, C.G. Unson, and A.M. Spiegel The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family J. Biol. Chem. 266 1991 9309 9313
130. M. Shiraishi, K. Kato, S. Terao, Y. Ashida, Z. Terashita, and G. Kito Quinones. 4. Novel eicosanoid antagonists: synthesis and pharmacological evaluation J. Med. Chem. 32 1989 2214 2221
131. Y. Shiraishi, K. Asano, T. Nakajima, T. Oguma, Y. Suzuki, T. Shiomi, K. Sayama, K. Niimi, M. Wakaki, J. Kagyo, E. Ikeda, H. Hirai, K. Yamaguchi, and A. Ishizaka Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor J. Pharmacol. Exp. Ther. 312 2005 954 960
132. W.L. Smith Prostanoid biosynthesis and mechanisms of action Am. J. Physiol. 263 1992 F181 F191
133. I. Spik, C. Brenuchon, V. Angeli, D. Staumont, S. Fleury, M. Capron, F. Trottein, and D. Dombrowicz Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse J. Immunol. 174 2005 3703 3708
134. Y. Sugimoto, A. Yamasaki, E. Segi, K. Tsuboi, Y. Aze, T. Nishimura, H. Oida, N. Yoshida, T. Tanaka, M. Katsuyama, K. Hasumoto, T. Murata, M. Hirata, F. Ushikubi, M. Negishi, A. Ichikawa, and S. Narumiya Failure of parturition in mice lacking the prostaglandin F receptor Science 277 1997 681 683
135. H. Sugimoto, M. Shichijo, T. Iino, Y. Manabe, A. Watanabe, M. Shimazaki, F. Gantner, and K.B. Bacon An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro J. Pharmacol. Exp. Ther. 305 2003 347 352
136. Y. Takahashi, S. Tokuoka, T. Masuda, Y. Hirano, M. Nagao, H. Tanaka, N. Inagaki, S. Narumiya, and H. Nagai Augmentation of allergic inflammation in prostanoid IP receptor deficient mice Br. J. Pharmacol. 137 2002 315 322
137. J. Tamaoki, M. Kondo, J. Nakata, Y. Nagano, K. Isono, and A. Nagai Effect of a thromboxane A(2) antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma Chest 118 2000 73 79
138. T. Tanabe, and V. Ullrich Prostacyclin and thromboxane synthases J. Lipid Mediators Cell Signal. 12 1995 243 255
139. S. Terao, M. Shiraishi, T. Matsumoto, and Y. Ashida Thromboxane A2 antagonist-discovery of seratrodast Yakugaku Zasshi 119 1999 377 390
140. S.L. Tilley, T.M. Coffman, and B.H. Koller Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes J. Clin. Invest. 108 2001 15 23
141. K. Tokiyoshi, T. Ohnishi, and Y. Nii Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage Surg. Neurol. 36 1991 112 118
142. A. Ueno, K. Tanaka, and M. Katori Possible involvement of thromboxane in bronchoconstrictive and hypertensive effects of LTC4 and LTD4 in guinea pigs Prostaglandins 23 1982 865 880
143. Y. Urade, K. Watanabe, and O. Hayaishi Prostaglandin D, E, and F synthases J. Lipid Mediators Cell Signal. 12 1995 257 273
144. van den Toorn, L.M., 2004. Clinical implications of airway inflammation in mild intermittent asthma. Ann. Allergy Asthma Immunol. 92, 589-594; quiz 595-587, 658.
145. G.A. Vielhauer, H. Fujino, and J.W. Regan Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor Arch. Biochem. Biophys. 421 2004 175 185
146. A.M. Vignola, F. Mirabella, G. Costanzo, R. Di Giorgi, M. Gjomarkaj, V. Bellia, and G. Bonsignore Airway remodeling in asthma Chest 123 2003 417S 422S
147. L. Walch, V. de Montpreville, C. Brink, and X. Norel Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins Br. J. Pharmacol. 134 2001 1671 1678
148. K. Watanabe Prostaglandin F synthase Prostaglandins Other Lipid Mediat. 68-69 2002 401 407
149. S.E. Wenzel Arachidonic acid metabolites: mediators of inflammation in asthma Pharmacotherapy 17 1997 3S 12S
150. S.E. Wenzel, J.Y. Westcott, H.R. Smith, and G.L. Larsen Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators Am. Rev. Respir. Dis. 139 1989 450 457
151. S.E. Wenzel, J.Y. Westcott, and G.L. Larsen Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses J. Allergy Clin. Immunol. 87 1991 540 548
152. J.H. Widdicombe, I.F. Ueki, D. Emery, D. Margolskee, J. Yergey, and J.A. Nadel Release of cyclooxygenase products from primary cultures of tracheal epithelia of dog and human Am. J. Physiol. 257 1989 L361 L365
153. L.G. Wood, D.A. Fitzgerald, P.G. Gibson, D.M. Cooper, and M.L. Garg Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma Lipids 35 2000 967 974
154. A. Xiang, Y. Uchida, A. Nomura, H. Iijima, T. Sakamoto, Y. Ishii, Y. Morishima, K. Masuyama, M. Zhang, K. Hirano, and K. Sekizawa Involvement of thromboxane A(2) in airway mucous cells in asthma-related cough J. Appl. Physiol. 92 2002 763 770
155. H. Yamada, H. Kotaki, H. Furitsu, Y. Sawada, and T. Iga Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: study using DBA/2N mice Biopharm. Drug Dispos. 20 1999 271 276
156. Zheng, L., Duan, S.F., Zhang, Z.X., 1991. Changes of thromboxane A2 (TXA2) and prostacyclin (PGI2) in COPD patients with pulmonary hypertension. Zhonghua Nei Ke Za Zhi 30, 91-93, 126